GW Pharmaceuticals has announced promising results from its phase 2 study that investigated whether cannabidiol (CBD) and tetrahydrocannabinol (THC) can help patients suffering from brain cancer.
They study tested the safety and efficacy of THC and CBD on 21 patients suffering from aggressive brain tumours. The results were promising:
- Patients treated with GW’s drug had an 83% one-year survival rate, compared with 53% for the patients with the placebo.
- GW's cannabis based drug increased the median survival to over 550 GW's days compared with just 369 days of the placebo treatment.
- The drug also fared well on all the safety parameters and was well-tolerated by the patients.
A placebo is a substance that has no therapeutic effect, and is used as a control in testing new drugs.
Justin Glover, GW’s CEO said the data from the trial would lead to further clinical programmes investigating the effect of cannabis on other forms of cancer
"This study further reinforce[s] the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma,”
GW has also had great success treating severe Epilepsy with cannabis-based drugs. It plans to make its treatment, Epidolex available to both US and European authorities during 2017.
Contrary to the increasing body of medical and and scientific research suggesting otherwise the UK Government still believes that cannabis can only “unquestionably cause harm to individuals and society”.
GW Pharma’s cannabis drug helps cancer patients
Reply With Quote
Bookmarks